SCHEMBL2716237

SCHEMBL2716237

COC(=O)c1cc(C(=O)O)ccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.68
KDM5C P41229 5/20 0.68
KDM6B O15054 3/20 0.68
KDM4C Q9H3R0 3/20 0.68
KDM2A Q9Y2K7 3/20 0.68
KDM3A Q9Y4C1 3/20 0.68
FTO Q9C0B1 8/20 0.67
ALKBH5 Q6P6C2 5/20 0.67
KDM4A O75164 4/20 0.67
KDM5B Q9UGL1 3/20 0.67
ALDH1A1 P00352 2/20 0.67
TET3 O43151 1/20 0.67
BBOX1 O75936 1/20 0.67
MAPT P10636 1/20 0.67
KDM5A P29375 1/20 0.67
ASPH Q12797 1/20 0.67
KDM4D Q6B0I6 1/20 0.67
TET2 Q6N021 1/20 0.67
KDM7A Q6ZMT4 1/20 0.67
KDM8 Q8N371 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30745026 1.00 KDM4E (0.68) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL70350 0.89 KDM4E (0.62) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL30065796 0.89 KDM4E (0.62) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL30779113 0.86 KDM4E (0.68) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL475565 0.86 KDM4E (0.68) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL4939178 0.86 KDM4E (0.50) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL30236802 0.86 KDM4E (0.50) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL4612998 0.85 FTO (0.71) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL8868177 0.84 ALDH1A1 (0.51) KDM4EKDM5CKDM6BKDM4CKDM2A
SCHEMBL13545747 0.83 KDM4E (0.53) KDM4EKDM5CKDM6BKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148752-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM BIOME BIOPLASTICS LIMITED (GB) 2018-05-31 US claimed
EP-3307901-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM Biome Bioplastics Limited (GB) 2018-04-18 EP claimed
CN-104363887-B Compositions, methods and uses comprising pyridine dicarboxylic acid esters and esters of glucose and fatty acids 莱雅公司 2017-11-10 CN claimed
CN-107106452-A Specific pyridinedicarboxylicacid acid derivatives/antioxidant combination 欧莱雅 2017-08-29 CN claimed
WO-2016202875-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM BIOME BIOPLASTICS LIMITED (GB) 2016-12-22 WO claimed
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-08-04 US claimed
US-20260085336-A1 NEW POLYMERS AND METHODS BIOME BIOPLASTICS LTD (GB) 2026-03-26 US disclosed
EP-4663242-A1 TARGETING THE ENERGY COUPLING FACTOR (ECF) TRANSPORTERS AS NOVEL ANTIMICROBIAL TARGET Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-12-17 EP disclosed
US-12454710-B2 Process for the preparation of 2,4- or 2,5-pyridinedicarboxylic acid and copolymers derived therefrom BIOME BIOPLASTICS LIMITED (GB) 2025-10-28 US disclosed
US-12415793-B2 Modulators of TMEM16A for treating respiratory disease TMEM16A LIMITED (GB) 2025-09-16 US disclosed
WO-2025104079-A1 SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-05-22 WO disclosed
US-20240287562-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM BIOME BIOPLASTICS LIMITED (GB) 2024-08-29 US disclosed
CN-114269433-B Modulators of TMEM16A for the treatment of respiratory diseases TMEM16A有限公司 2024-08-02 CN disclosed
US-6673799-B1 INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-01-06 US disclosed
EP-1122242-A1 CYANOPHENYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2001-08-08 EP disclosed
EP-0573467-B1 NEUROLEPTIC PERHYDRO-1H-PYRIDO 1,2-a]PYRAZINES PFIZER (US) 1995-05-31 EP disclosed
EP-0573467-A1 NEUROLEPTIC PERHYDRO-1H-PYRIDO 1,2-a]PYRAZINES. PFIZER (US) 1993-12-15 EP disclosed
US-5157034-A Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines PFIZER INC. (US) 1992-10-20 US disclosed
WO-1992015580-A1 NEUROLEPTIC PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES PFIZER INC. (US) 1992-09-17 WO disclosed
CN-1060655-A 4-or 5-substituted pyridines-2-carboxylic acid, their preparation method and medicinal HOECHST AG (DE) 1992-04-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415793-B2 Modulators of TMEM16A for treating respiratory disease TMEM109, CFTR, TMEM120A KDM4E 3220/4885KDM5C 4247/4885KDM6B 3222/4885
US-12454710-B2 Process for the preparation of 2,4- or 2,5-pyridinedicarboxylic acid and copolymers derived therefrom HPD, PCCA, MVD KDM4E 657/4885KDM5C 536/4885KDM6B 484/4885
US-20260085336-A1 NEW POLYMERS AND METHODS PGD, HPD, UROD KDM4E 286/4885KDM5C 315/4885KDM6B 269/4885
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation HEXD, CDK5, CHUK KDM4E 2612/4885KDM5C 606/4885KDM6B 2412/4885
US-20180148752-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM HPD, PCCA, MVD KDM4E 657/4885KDM5C 536/4885KDM6B 484/4885
US-20240287562-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM HPD, PCCA, MVD KDM4E 631/4885KDM5C 548/4885KDM6B 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.